AKT1 and hearing loss disorder: They also reported that mTORC2/Akt is involved in the regulation of hair cell survival in the cisplatin exposure condition, suggesting that the therapeutic activation of mTORC2 in conjunction with decreasing mTORC1 might represent a promising and effective strategy in preventing hearing loss [37].